单剂卡巴喹-吡咯萘啶联合治疗急性无并发症恶性疟的2a期研究
CAPTURE 1是一项多中心开放标签2a期研究,纳入38例12-55岁急性无并发症恶性疟原虫单感染患者,评估单剂口服卡巴喹-吡咯萘啶的安全性和疗效。
要点
- 单剂卡巴喹-吡咯萘啶在成人及青少年恶性疟中显示良好安全性,不良事件多为轻中度。
- 研究因暴露量高于预测及2天给药方案担忧提前终止,支持后续更大规模试验。
核心结论
- 单剂卡巴喹-吡咯萘啶在成人及青少年急性无并发症恶性疟中显示良好的安全性和疗效,支持进一步开发。
研究设计与样本
- 多中心、开放标签、2a期研究(CAPTURE 1),在非洲四国五家医院纳入38例12-55岁急性无并发症恶性疟原虫单感染患者。
- A部分12例接受单剂330 mg卡巴喹游离碱和360 mg吡咯萘啶四磷酸盐;B部分26例接受660 mg卡巴喹和720 mg吡咯萘啶(按体重调整)。
关键数值与推荐
- 排除混合疟原虫感染、重症疟疾、肝脏异常及既往抗疟药使用。
- 主要结局为安全性和第28天PCR校正ACPR。
临床怎么用
- 该方案为单剂口服联合治疗,可能简化疟疾治疗流程,但需更大规模试验验证。
- 研究中因暴露量高于预测及2天给药方案担忧提前终止,临床使用需关注剂量优化。
局限性
- 研究为开放标签、非对照、小样本2a期试验,结果需进一步验证。
- 试验提前终止,B1、B2和B3队列未启动,可能影响结论的稳健性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Novel antimalarial combinations are needed to address the threat of emerging resistance to artemisinins. This study evaluated the safety, tolerability, pharmacokinetics, and efficacy of a single oral dose of cabamiquine-pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria. METHODS: This two-part, multicentre, open-label, phase 2a study (CAPTURE 1) enrolled patients aged 12-55 years from five hospitals in four countries across Africa with acute uncomplicated P falciparum monoinfection, defined by microscopically confirmed parasitaemia, with parasite densities of 1000-50 000 asexual parasites per μL in part A and 1000-150 000 asexual parasites per μL in part B; exclusions included mixed Plasmodium infections, severe malaria, liver abnormalities, and previous antimalarial use. In part A, patients received a single oral dose of 330 mg cabamiquine free base and 360 mg pyronaridine tetraphosphate. In part B (cohort B0), patients received 660 mg cabamiquine and 720 mg pyronaridine adjusted for bodyweight. Additional planned cohorts B1, B2, and B3 (control) were not initiated owing to early trial termination after cohort B0 in part B following higher-than-predicted cabamiquine exposure, data monitoring committee concerns about 2-day dosing, and high observed efficacy in the studied cohorts. The primary outcomes were safety and tolerability, assessed through the incidence, severity, and seriousness of study intervention-related treatment-emergent adverse events (TEAEs), and day 28 post-treatment efficacy in treated patients assessed using PCR-corrected adequate clinical and parasitological response (ACPR). This study is registered with ClinicalTrials.gov, NCT05689047, and is complete. FINDINGS: Between March 29, 2023, and May 8, 2024, 75 patients were screened, of whom 38 patients were enrolled (12 in part A and 26 in part B) and treated in the study. TEAEs occurred in 25 (65·8%) of the 38 patients and were predominantly mild or moderate in severity (grade 1 or 2), and no serious adverse events or deaths were reported. The day 28, PCR-corrected ACPR in part A was 91·7% (11 of 12 patients [95% CI 64·6-98·5]) and 92·3% (24 of 26 patients [95% CI 75·9-97·9]) in part B. INTERPRETATION: A single dose of cabamiquine-pyronaridine showed promising safety and efficacy in this proof-of-concept trial in adults and adolescents, which supports further development for combination therapy in larger trials and in children. FUNDING: Merck KGaA, the EDCTP2 Programme, and the Swedish International Development Cooperation Agency (Sida).
引用
- Mombo-Ngoma G, Adoke Y, Manego RZ, et al. Safety, pharmacokinetics, and antimalarial efficacy of single-dose cabamiquine-pyronaridine combination therapy for the treatment of adults and adolescents with acute uncomplicated Plasmodium falciparum malaria (CAPTURE 1): a prospective, multicentre, open-label, phase 2a study. Lancet Infect Dis. 2026. PMID: 42462745. doi:10.1016/S1473-3099(26)00233-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。